In this issue:
CAVE: cetuximab rechallenge efficacious for RAS wild-type metastatic CRC
Checkpoint inhibitors may offer PFS benefits in MSS disease without liver metastases
Cytoreductive surgery and HIPEC ± perioperative systemic therapy for CRC peritoneal metastases
Nomogram for prognostication of MSI-high metastatic CRC undergoing checkpoint inhibitor therapy
Use of molecular assays and circulating tumour DNA in early-stage CRC
MMR gene alteration and BRAFV600E mutation may be prognostic for response to checkpoint inhibitors
Markers of benefit from FOLFOXIRI/ bevacizumab in patients with BRAF-mutated metastatic CRC
Severe early treatment-related toxicity to front-line chemotherapy regimens
Greater risk for metachronous peritoneal metastases in pT4a versus pT4b colon cancer
Survival benefit of repeat local treatment in patients suffering from early recurrence of liver metastases
Please login below to download this issue (PDF)